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Abstract
Aim To investigate the impact of an entire episode of herpes
zoster (HZ) or post-herpetic neuralgia (PHN) on an individual’s
quality of life (QoL).
Subjects and methods Individuals aged ≥50 years with pain-
ful HZ in the previous 5 years were identified across six
European countries (Spain, Portugal, The Netherlands, Bel-
gium, Sweden and Switzerland). They participated in a
survey comprising bespoke questions to evaluate their pre-
vious HZ/PHN episode.
Results A total of 1,005 individuals participated, 874 (87%)
having had HZ, and 13% having had PHN. Generally, pain
and QoL outcomes were similar irrespective of when HZ
was diagnosed (≤12 versus 13–60 months) and age (50–59
versus ≥60 years). Mean pain scores were significantly
higher in those with PHN versus HZ both on average (7.2
versus 6.4) and at worst (8.3 versus 7.4). PHN had a signif-
icantly higher impact on patients’ perception of their overall
QoL, with 37% reporting a high impact (HZ: 19%). Pain
restrictions in the following QoL domains significantly im-
pacted on the respondents’ perception of QoL: enjoyment of
life (level of impact, 31%), general activity (29%), mood
(25%), sleep (8%) and walking ability (8%), and were
significantly higher in those with PHN than in those with
HZ. Sleep was the area worst affected.
Conclusion HZ, and particularly PHN, is associated with
considerable levels of pain that have a significant impact on
the QoL of participants across six European countries.
Keywords Europe . Herpes zoster . Pain . Post-herpetic
neuralgia . Quality of life
Introduction
Herpes zoster (HZ), also known as shingles, is the clinical
manifestation of the reactivation of latent varicella zoster virus
(VZV), which as a primary infection causes varicella or chick-
enpox (Lungu et al. 1995). HZ is a potentially serious and
debilitating condition characterised by a unilateral vesicular
rash and is usually accompanied by acute pain (Arvin 2005;
Hope-Simpson 1965). The most frequent and debilitating
complication of HZ is post-herpetic neuralgia (PHN), a per-
sistent neuropathic pain syndrome (Hope-Simpson 1975;
Schmader 2001, 2008). Although there is no standard defini-
tion of PHN, it is often defined as pain that persists for
≥90 days after the onset of HZ rash (Schmader et al. 2008).
The incidence and severity of HZ and PHN increase
strikingly with age (Gauthier et al. 2009; Hope-Simpson
1975; Yawn et al. 2007), and are associated with an age-
related decline in VZV-specific cell-mediated immunity
(Arvin 2005; Levin et al. 2008). Approximately one in four
people will develop HZ during their lifetime (Brisson et al.
2001; Yawn et al. 2007), with the risk increasing to one in
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two in those aged ≥85 years (Schmader 2001). On average,
10–20% of HZ patients will develop PHN, which can persist
for years or even decades after the HZ rash has gone, with
rates of 25–50% reported in patients over 50 years old,
depending on the definition used (Johnson et al. 2007; Scott
et al. 2003). As populations age, the number of cases of HZ
and PHN is expected to rise (Dworkin et al. 2008).
Several observational studies have demonstrated that HZ
pain/PHN have a significant impact on quality of life (QoL)
(Drolet et al. 2010; Katz et al. 2004; Lydick et al. 1995;
Schmader et al. 2007; van Seventer et al. 2006). These were
prospective studies and, as a result, employed instruments that
evaluated the burden of HZ/PHN at specific time points while
the patient was suffering from HZ pain/PHN. A retrospective
survey was undertaken to assess the impact of the entire HZ/
PHN episode on QoL in a German population aged ≥50 years
that had experienced painful HZ during the past 5 years
(Weinke et al. 2010). This was the first study to employ a
unique evaluation that provided information regarding the
impact of the burden of HZ pain/PHN over the entire HZ/
PHN episode rather than at specific time points while the
patient had HZ/PHN. This retrospective approach also en-
abled the inclusion of a statistically sufficient number of 280
individuals, and provided a broader view of the impact of the
burden of HZ/PHN on QoL by capturing both pain severity
and duration. The results of this German retrospective survey
demonstrated that those with HZ and PHN experience high
levels of pain affecting many areas of their lives, including
daily activities, mobility, work, sleep and mood. Furthermore,
those with PHN have consistently worse outcomes in terms of
pain and QoL than those with HZ. These results confirmed
data reported in observational studies (Drolet et al. 2010; Katz
et al. 2004; Lydick et al. 1995; Schmader et al. 2007; van
Seventer et al. 2006) and contributed to increased awareness
of the significant burden of HZ/PHN.
Our survey was an expansion of the previously reported
German survey (Weinke et al. 2010) to assess the impact of
HZ and PHN on the QoL of those aged ≥50 years who had
experienced painful HZ during the past 5 years. Data from
six other European countries are reported.
Subjects and methods
Study setting and participants
Between December 2008 and February 2009, a survey was
administered by TNS Healthcare (Munich, Germany), to
members of the public in Spain, Portugal, The Netherlands,
Belgium, Sweden and Switzerland. A representative sample
among individuals aged ≥50 years in private households
was identified by free-random sampling. Press adverts were
also published in Portugal. In addition, Omnibus™ (a
quantitative multi-purpose survey) was used as a pre-
screening tool to identify individuals aged ≥50 years in
The Netherlands and Switzerland.
Computer-assisted telephone interviews were conducted
in Spain, Portugal, Belgium, Sweden and Switzerland.
Online, computer-assisted self-interviews were employed
in The Netherlands.
A total of 44,545 individuals identified as aged ≥50 years
were contacted to determine if they had: (1) been diagnosed
with HZ by a physician during the previous 5 years; and (2)
experienced HZ-related pain and would therefore be eligible
to participate in this survey. Eligible participants were clas-
sified, according to the duration of pain, as those with HZ
(pain lasting <3 months after HZ rash onset) or those with
PHN (pain lasting ≥3 months after HZ rash onset).
Survey design
The interview lasted ∼20 min and consisted of 22 closed
questions (those that can usually be answered by ‘yes’ or
‘no’; providing a specific, simple piece of information; using
a numeric scale; or by selecting an answer from a multiple-
choice list). The questionnaire comprised bespoke questions of
which some were informed from standard QoL questionnaires
and further developed to enable the evaluation of the complete
course of a previous HZ/PHN episode. QoL domains covered
by the questions were interference of pain with usual daily
activities (including getting out of the house, going shopping,
concentrating on mental tasks, being touched by another per-
son and self-care such as putting on clothes and taking a
shower or bath), mobility (walking ability), normal work
(including both work outside the home and housework), sleep,
mood, anxiety and/or depression, enjoyment of life, enjoying
simple leisure activities (such as reading a book, listening to
the radio or watching television) and social/family relations.
Participants assessed pain on a scale from 00‘no pain’ to
100‘pain as bad as you can imagine’. They assessed the
interference of HZ pain/PHN on QoL domains on a scale of
00‘does not interfere’ to 100‘completely interferes’ with
activity.
All interviews (and the screening process) were carried
out in the native language of each country by interviewers
who had received comprehensive training regarding the
questionnaire. The questionnaire was translated from En-
glish into the local language, and was back-translated into
English and compared with the original to validate the
accuracy of the translation.
Statistical analyses
Significant differences in pain and QoL outcomes were tested
using 90% confidence intervals (p<0.1) for proportions and
means for the following subgroups: (1) those with HZ
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diagnosed during the previous 12 months versus those with
HZ diagnosed between 13 months and 60 months ago; (2)
those aged 50–59 years versus those aged ≥60 years; (3) those
classified as having HZ versus those classified as having
PHN. Significant differences in outcomes were also tested
for each country versus those across all countries.
Multiple regression analyses were undertaken to determine
which areas of pain interference had a significant impact on
the respondents’ perception of their QoL. Measurement was
by standardised β-coefficients. Normalised values (e.g. areas
that have an impact on overall QoL) were set as 100%.
Results are presented for the overall population across the
six countries unless specified otherwise.
Results
Patient characteristics
Of 44,545 individuals aged ≥50 years contacted across six
European countries, 1,005 individuals who had experienced
painful HZ diagnosed by a physician during the previous
5 years were identified. Across all six countries, 874
respondents were classified as having had HZ (87%; pain
lasting <3 months after rash onset) and 131 were classified
as having had PHN (13%; pain lasting ≥3 months after rash
onset). Of these, 323 (32%) were diagnosed with HZ or
PHN during the previous 12 months. Similar numbers of
respondents were aged 50–59 years (n0454; 45%) and
≥60 years (n0551; 55%). Table 1 shows the distribution of
the respondents in the six countries.
The mean age of respondents was 63 years, and most were
women (66%; Table 2). One in three of all respondents was
employed (full- or part-time), including 59% of those aged
50–59 years and 13% of those aged ≥60 years (Table 2).
Many respondents (40%) reported being nervous or
stressed and 24% felt sad/depressed or lonely prior to
noticing the first symptoms of HZ.
Patient-reported pain
In general, pain and QoL outcomes were similar irrespective
of when HZ was diagnosed (≤12 months versus 13–
60 months) and age (50–59 years versus ≥60 years). In
contrast, every pain and QoL outcome was generally worse
in those with PHN compared with those with HZ.
HZ pain/PHN were characterised as ‘burning’ (56% of
respondents), ‘itching’ (49%), ‘stabbing’ (40%), ‘shooting’
(21%), ‘throbbing’ (11%), ‘electric shocks’ (10%) and ‘pain-
ful cold’ (7%; respondents could use more than one word to
describe their pain). Pain was also characterised as ‘continu-
ous, steady and constant’ by 45% of respondents, and ‘rhyth-
mic, periodic and intermittent’ by 34%. More respondents
with PHN characterised their pain as ‘continuous, steady and
constant’ (52%) compared with those with HZ (45%).
Mean pain scores were 6.5 on average and 7.5 at its worst
(Table 3). High pain scores (between 8 and 10) were
reported by 33% of respondents when describing their av-
erage pain level, and by 56% of respondents describing pain
at its worst. As expected, significantly higher mean pain
scores, both on average and at its worst, were reported by
those with PHN compared with those with HZ, with signif-
icantly more of those with PHN reporting high pain scores
(8–10) on average and at its worst (Table 3).
Despite 89% of respondents receiving treatment for HZ/
PHN, 37% did not receive it within 72 h of rash onset. Only
15% of respondents reported total pain relief, 5% reported no
pain relief, with mean levels of pain relief being 64%. Overall,
those with PHN received significantly more medications than
those with HZ (mean: 2.2 per person versus 1.7, respectively),
with significantly more of those with PHN receiving 4 or 5
medications. However, despite receiving significantly more
medications, those with PHN experienced significantly less
pain relief, compared with those with HZ (mean pain relief:
50% versus 66%, respectively), with significantly more
patients not achieving any pain relief (4% versus 12%,
respectively).
Table 1 Distribution of participants
Total (N) n (%)
HZ/PHN ≤12 months HZ/PHN >12–60 months Age 50–59 years Age ≥60years HZ PHN
Total 1,005 323 (32) 682 (68) 454 (45) 551 (55) 874 (87) 131 (13)
Spain 253 93 (37) 160 (63) 126 (50) 127 (50) 211 (83) 42 (17)
Portugal 151 50 (33) 101 (67) 57 (38) 94 (62) 133 (88) 18 (12)
The Netherlands 242 69 (29) 173 (71) 102 (42) 140 (58) 208 (86) 34 (14)
Belgium 108 21 (19) 87 (81) 51 (47) 57 (53) 97 (90) 11 (10)
Sweden 101 30 (30) 71 (70) 46 (46) 55 (54) 93 (92) 8 (8)
Switzerland 150 60 (40) 90 (60) 72 (48) 78 (52) 132 (88) 18 (12)
HZ herpes zoster; PHN post-herpetic neuralgia
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Side effects related to the medication used to treat HZ
were reported by 26% of those who received medication.
Most of the side effects reported were somnolence, stomach
pain and vertigo.
Impact of HZ and PHN on QoL
Restrictions in the following QoL domains had a significant
impact on the respondents’ perception of QoL, as shown by
multiple regression analysis (adjusted R2: 0.36): enjoyment
of life (level of impact: 31%), general activity (29%), mood
(25%), sleep (8%) and walking ability (8%). The impact of
normal work and relations with others on the perception of
QoL were not statistically significant.
Figure 1 and Table 3 illustrate that HZ pain/PHN inter-
fered with every QoL domain. Furthermore, each outcome
was generally worse in those with PHN versus those with
HZ. Further details on the QoL domains are provided below.
Interference with daily activities
The effect of pain on usual daily life was assessed in depth.
Multiple regression analysis demonstrated that restrictions
in the following aspects of daily life due to pain had a
significant impact on the respondents’ perception of QoL
(adjusted R2 for all: 0.43): going shopping (level of impact:
27%), concentrating on mental tasks (25%), being touched
by a person (indicative of cutaneous allodynia – pain result-
ing from a non-noxious stimulus to normal skin or the scalp:
19%), getting out of the house (19%) and putting on clothes
(10%). Interference with ‘getting out of the house’ and
‘going shopping’ had the highest impact on the respondents’
perception of QoL in those with PHN (38% and 40%,
respectively) according to multiple regression analysis.
In addition to interfering with all usual daily activities
and self-care, many respondents also reported limitations in
moderate physical efforts (61%) and climbing a flight of
stairs (43%) due to HZ/PHN (Table 3).
Mobility
As well as affecting walking ability, HZ pain/PHN resulted
in a significant number of respondents being confined to bed
(16% of those with PHN versus 6% of those with HZ).
Work
Of the 52% of respondents aged 50–59 years who were
employed while affected by HZ/PHN, 48% reported ab-
sence from work as a result of HZ/PHN. The reasons for
work absence were mainly healthcare visits (48%), pain
(37%), discomfort (38%) and inability to concentrate
(28%). Pain (48%) and discomfort (45%) were the most
common reasons for work absence in the 25% of those aged
≥60 years who were employed. Those with PHN reported
significantly more work absences than those with HZ, with
pain being the most common reason for the absences.
Sleep
HZ pain/PHN interfered with sleep to a greater extent than all
other areas of QoL tested (Fig. 1). Overall, 55% of respond-
ents reported ‘not getting sufficient sleep’ at least some of the
time due to HZ/PHN. Furthermore, sleep was ‘not quiet’ for at
least some of the time in 66% of respondents (64% of those
with HZ, 78% of those with PHN). Significantly more patients
with PHN reported that sleep was ‘not quiet’ all of the time
(18% versus 8% of those with HZ).
Table 2 Characteristics of participants
All Age (years) Patient category
50–59 ≥60 HZ PHN
All, n (%) 1,005 (100) 454 (45) 551 (55) 874 (87) 131 (13)
Female, n (%) 666 (66) 305 (67) 361 (66) 587 (67) 79 (60)
Age, mean years (SD) 62.8 (9.2) 54.6 (3.1) 69.6 (6.8) 62.5 (9.1) 65.1 (9.9)
Employment status, n (%)
Full-time 232 (23) 188 (41) 44 (8) 211 (24) 21 (16)
Part-time 107 (11) 78 (17) 29 (5) 92 (11) 15 (11)
Housewife/house-husband 149 (15) 78 (17) 71 (13) 131 (15) 18 (14)
Unemployeda 89 (9) 57 (13) 32 (6) 80 (9) 9 (7)
Retired 428 (43) 53 (12) 375 (68) 360 (41) 68 (52)
a In Switzerland, the term ‘unemployed’ includes ‘unemployed at the moment’, ‘not employed, reason unknown’, ‘other’ and ‘self-employed’.
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Mood
In addition to affecting mood and enjoyment of life, HZ
pain/PHN was associated with anxiety and/or depression in
31% of respondents, with significantly more respondents
with PHN reporting extreme anxiety/depression (11% ver-
sus 5% of those with HZ, Table 3).
Overall, 29% of respondents reported very rarely/rarely
enjoying simple leisure activities such as reading a book,
listening to the radio or watching television while suffering
from HZ/PHN (Table 3). More respondents with PHN
reported very rarely/rarely enjoying simple leisure activities
than those with HZ, with significantly more very rarely
enjoying leisure activities (25% versus 14%, respectively).
Social/family relations
More respondents with PHN reported consequences for
family members and their social circle, compared with those
with HZ (54% versus 42%, respectively; Table 3). Overall,
20% of respondents reported that they specifically felt iso-
lated from their family and friends for at least some of the
Table 3 Pain and quality of daily living outcomes
All Age (years) Patient category
50–59 ≥60 HZ PHN
Level of pain
Pain score (0–10), mean
Average 6.5 6.3 6.6* 6.4 7.2*
At worst 7.5 7.5 7.5 7.4 8.3*
High pain score (8–10), % respondents
Average 33 30 35* 30 47*
At worst 56 57 55 53 74*
Limitations on daily activities
Usual daily activities (0–10), mean score
Taking a shower or bath 3.5 3.3 3.6 3.4 4.2
Being touched by a person 3.8 3.7 3.9 3.6 5.3
Putting on clothes 3.5 3.4 3.6 3.4 4.5
Getting out of the house 3.2 3.0 3.3 3.0 4.3
Concentrating on mental tasks 3.2 3.2 3.2 3.1 4.0
Going shopping 3.5 3.5 3.5 3.4 4.4
Self-care, % respondents 27 29 26 26 37
Moderate physical efforts, % respondentsa
Limited at least a bitb 61 63 60 61 66
Limited a lot 20 20 20 18 36*
Climbing a flight of stairs, % respondents
Limited at least a bitb 43 46 40 41 56
Limited a lot 13 12 14 10 29*
Consequences for family members and social circle, % respondentsc 44 47 40 42 54
Feelings of anxiety/depression and enjoyment of leisure activities, % respondents
Anxiety/depression
At least moderated 31 30 32 29 43
Extreme 6 6 6 5 11*
Did not enjoy leisure activitiese 29 30 28 27 41
*p<0.1 versus corresponding group
aModerate physical efforts included relocating a table, vacuum cleaning, or playing bowls
b Limited at least a bit includes ‘limited a bit’ and ‘limited a lot’
c Consequences for family members and social circle includes ‘few consequences’, ‘moderate consequences’ and ‘severe consequences’
d At least moderate includes ‘moderate’ and ‘extreme’
e Did not enjoy leisure activities includes ‘rarely’ and ‘very rarely’
HZ herpes zoster; PHN post-herpetic neuralgia
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time while suffering from HZ/PHN, resulting in reduced
communication (19% and 27% for HZ and PHN,
respectively).
Effect of HZ and PHN on overall health status
and concomitant conditions
Overall, 31% of respondents perceived HZ/PHN to have had a
moderate/severe impact on their overall health status, as mea-
sured on a five-point scale from ‘no impact’ to ‘severe im-
pact’. Significantly more respondents with PHN reported this
level of impact on their overall health status compared with
those with HZ (54% versus 24%, respectively).
In addition, up to 46% of respondents who had co-
morbid conditions reported some degree of deterioration in
those conditions while suffering from HZ/PHN, including
osteoarthritis (38% reported deterioration), rheumatoid ar-
thritis (45%), coeliac disease (46%) asthma (42%), heart
failure (40%) and diabetes (39%).
Overall impact on QoL
HZ/PHN had a considerable impact on respondents’ overall
perception of their QoL (Fig. 2). Overall, 21% of respond-
ents perceived the impact of HZ/PHN on their overall QoL
to be 8 to 10, on a 10-point scale of 00‘not affected’ to
100‘highly affected’. PHN had a significantly higher im-
pact on the respondents’ perception of their overall QoL
(Fig. 2).
Country data
Country results that were significantly different from those
for all respondents are highlighted.
Patient-reported pain
Significantly more respondents in Portugal and Belgium




































Fig. 1 Interference of herpes
zoster (HZ) pain/post-herpetic
neuralgia (PHN) on seven
aspects of quality of daily life.
Pain interference measured on a
scale of 0 (‘does not interfer’)
to 10 (‘completely interferes’)
with activity. *p<0.1 for
those with PHN versus all




















High impact Medium impact Low impact
Fig. 2 Overall impact of herpes
zoster (HZ) pain/post-herpetic
neuralgia (PHN) on quality of
daily life. Pain interference with
overall quality of life on a scale
of 0 (‘not affected at all’) to 10
(‘highly affected’). Proportion
of those with high impact (score
8–10), medium impact (score
4–7) and low impact (score
0–3) across six European
countries. *p<0.1 for those
with PHN versus all
respondents and versus those
with HZ
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compared with all respondents (57% and 62%, respectively,
versus 45%). In The Netherlands, significantly more
respondents described their pain as ‘rhythmic, periodic and
intermittent’ (46% versus 34% for all respondents).
As shown in Table 4, Portuguese and Spanish respond-
ents reported significantly higher pain scores at worst, com-
pared with all respondents (7.9 and 8.0, respectively, versus
7.5); significantly more reported a high level of pain at its
worst (8–10; 65% and 67%, respectively, versus 56%) with
a significantly higher number reporting a pain score of 10 at
its worst (41% and 30% versus 19%). In contrast, those in
The Netherlands reported the lowest pain score at worst
(6.9), with significantly more reporting a medium pain score
(4–7; 67% versus 59% for all respondents).
Despite Spanish and Belgian respondents receiving a
similar number of medications to treat HZ as all respondents
(1.8 and 2.0 versus 1.8, respectively), they achieved signif-
icantly higher mean pain relief (70% and 69% versus 64%,
respectively). Significantly more Spanish and Belgium
respondents received their medication within 3 days of rash
onset (73% and 78%, respectively, versus 63% for all
respondents). Moreover, significantly more respondents in
The Netherlands and Sweden were treated with a single
medication (64% and 59% versus 45% for all respondents).
In contrast, Portuguese respondents received significantly
more medications (2.2 versus 1.8 for all respondents) but
achieved only similar mean pain relief as all respondents
(61% versus 64%).
Impact on various aspects of QoL
Overall, respondents from The Netherlands reported a sig-
nificantly higher impact on general activities, compared
with all respondents (interference score 5.1 versus 4.5)
(Table 4). Although the impact on general activities in
Portuguese respondents was not significantly different from
all respondents (interference score: 4.9 versus 4.5), signifi-
cantly more Portuguese respondents reported a high inter-
ference score (score 8–10; 30% versus 19%).
The impact of pain on mood was significantly higher in
Portuguese and Dutch respondents (interference score: 5.3,
5.2 versus 4.7 for all respondent; Table 4). In addition,
significantly more Portuguese respondents reported being
anxious and/or depressed while suffering from HZ/PHN
(51%) compared with all respondents (31%). Furthermore,
significantly more Portuguese respondents also reported
feeling sad/depressed or lonely prior to noticing the first
symptoms of HZ compared with all respondents (43%
versus 24%).
The impact of pain on walking ability was significantly
higher in The Netherlands (interference score: 4.5) compared
with all respondents (3.2) (Table 4). The Dutch also reported a
significantly higher impact of pain on normal work, compared
with all respondents (interference score: 5.0 versus 4.2). In
addition, the Dutch also reported a significantly higher impact
on relations with others compared with all respondents (inter-
ference score: 4.6 versus 3.5).
Table 4 Pain and quality of daily living outcomes by country
All Spain Portugal The Netherlands Belgium Sweden Switzerland
Level of pain
Pain score (0–10), mean
Average 6.5 6.7 6.7 6.3 6.5 6.3 6.1
At worst 7.5 8.0 7.9 6.9 7.2 7.2 7.5
High pain score (8–10), % respondents
Average 33 40 40 25 37 27 27
At worst 56 67 65 42 56 50 55
Interference of HZ pain/PHN on QoL domains, (0–10), mean
General activity 4.5 4.1 4.9 5.1 4.2 4.0 4.2
Mood 4.7 4.3 5.3 5.2 4.7 4.1 4.6
Walking ability 3.2 2.9 3.2 4.5 3.5 1.8 2.0
Normal work 4.2 3.7 4.3 5.0 4.5 3.4 4.1
Social relations 3.5 2.9 3.5 4.6 2.9 2.6 3.5
Sleep 4.9 4.6 5.0 5.2 5.4 4.4 4.7
Enjoyment of life 4.1 3.4 3.8 5.0 3.8 3.7 4.6
Perception of overall QoL, (0–10)
Mean 4.4 4.1 4.6 5.3 3.8 2.7 4.6
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The Belgians reported a significantly higher impact of
pain on sleep compared with all respondents (interference
score: 5.4 versus 4.9) (Table 4). The Dutch and Swiss
reported a significantly higher impact on enjoyment of life
compared with all respondents (interference score: 5.0, 4.6,
respectively, versus 4.1).
Overall impact on QoL
The overall impact on the respondents’ perception of QoL
was significantly higher in Dutch respondents compared
with all respondents (impact score: 5.3 versus 4.4), with
the Belgians and Swedish perceiving a lower impact (3.8
and 2.7, respectively) (Table 4). Significantly more Portu-
guese respondents reported a high impact score (8–10;
34%), compared with all respondents (21%).
Discussion
This large, pan-European, retrospective scientific survey of
patient-reported outcomes has expanded the findings of the
previously reported German survey (Weinke et al. 2010),
demonstrating that the burden of HZ, and particularly PHN,
are considerable in individuals ≥50 years old. The German
survey assessed patient-reported pain and QoL outcomes in
a sample of 280 affected individuals. The present survey
involved 1,005 additional individuals, and indicated that the
burden of HZ/PHN is similar across all six European
countries surveyed as well as in Germany (Weinke et al.
2010). As noted in the initial survey, pain and QoL out-
comes were not generally affected by age (50–59 years old
or aged ≥60 years). They were also not affected by time
since diagnosis (diagnosis ≤12 months or 13–60 months),
despite patients having to recall information from up to
5 years earlier. This suggests that HZ/PHN is a life event
that is not readily forgotten. These data also support the
results from earlier, prospective, observational studies (Katz
et al. 2004; Schmader et al. 2007; van Seventer et al. 2006).
Importantly, this large survey may help to increase the
awareness of the burden of HZ/PHN on QoL in different
countries, thereby leading to improved strategies for preven-
tion and management.
Prior to noticing the first symptoms of HZ, many of the
respondents in our survey reported feeling nervous or stressed
or sad/depressed or lonely. Stress and depression are recognised
risk factors for HZ and PHN (Irwin et al. 1998; Livengood
2000; Thomas and Hall 2004). Furthermore, one study dem-
onstrated that the VZV-specific cell-mediated immune re-
sponse in individuals aged <60 years with major depression
was similar to that found in those aged ≥60 years without
depression, suggesting that major depression reduces cell-
mediated immunity to VZV and is a risk factor for HZ that is
independent of age (Irwin et al. 1998).
HZ/PHN was associated with considerable pain. More
than half of all respondents reported a high level of pain at
its worst (pain score 8–10), including 3 out of 4 of those
with PHN. These results are not surprising and are similar to
other reports of HZ pain and PHN (Dworkin et al. 2008;
Johnson et al. 2010). Indeed, during the acute phase, HZ
pain has been described as more intense than post-surgical
or labour pain (Katz and Melzack 1999).
The burden of HZ/PHN on QoL was substantial. PHN
affected the respondents’ perception of QoL to a significant-
ly greater extent than HZ. These results are consistent with
previous reports of the interference of PHN with basic
activities and daily functioning (Oster et al. 2005; Schmader
2002; Schmader et al. 2007). Sleep was the most affected
QoL domain across all countries, with more than half of
respondents reporting not getting sufficient sleep due to
HZ/PHN. Lack of sleep is important because it has far-
reaching consequences. In addition to neurobehavioural
deficits such as lapses in attention, depression and cog-
nitive impairment, which can occur when sleep is re-
duced to <7 h per night for 14 days, restricted sleep has
also been associated with unhealthy physiological
changes (Banks and Dinges 2007). Lack of sleep also
reduces productivity, performance and safety outcomes,
and therefore has cost implications (Rosekind et al.
2010), which could be considerable, as one in three
respondents with HZ/PHN in this survey was employed. The
loss in productivity and associated cost implications related to
lack of sleep are in addition to those associated with absences
from work, which in the current survey were mainly due to
healthcare visits and pain. The indirect cost of work absence
was estimated to be €556 and €795 per case of HZ and PHN,
respectively, based on an average daily wage of €80, in one
European country, contributing to an annual cost to society of
€13 million in a single year (Gialloreti et al. 2010).
A clear correlation between increased intensity of pain and
greater interference with QoL has been reported (Lydick et al.
1995). However, the results from the individual countries
suggest that QoL can be significantly affected even in those
reporting less pain: those in The Netherlands reported the
lowest pain score at worst (6.9), with significantly more
reporting a medium pain score (4–7; 67%) compared with
all respondents (59%), but were the only participants to report
a significantly greater impact of HZ pain/PHN on their per-
ception of QoL. Furthermore, the Dutch were the only partic-
ipants to report a significantly higher impact on general
activities, walking ability, normal work and relations with
others, compared with all respondents.
Of note is that participants from Spain and Portugal
tended to report more intense pain than those in non-
Mediterranean countries, particularly those from The
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Netherlands. This is consistent with previous studies high-
lighting that cultural or ethnic factors may play a role in
subjects’ pain reports (Fillingim 2005). In a US National
Comorbidity Survey of subjects with serious health prob-
lems, Hispanics reported more pain than Caucasians
(Hernandez and Sachs-Ericsson 2006); the authors noted
that this may be related to cultural differences in the accept-
ability and the expression of distress. In a cross-cultural
study, women from The Netherlands with rheumatoid ar-
thritis reported lower levels of pain than Egyptian women
with comparable rheumatoid arthritis (Vlaar et al. 2007).
Many clinicians incorrectly perceive HZ to be a mild and
readily treatable disease (Johnson et al. 2010). In fact, treat-
ment options remain inadequate, particularly for those who
develop PHN, with potentially devastating effects on their
QoL in the acute and chronic phases (Coplan et al. 2004; Katz
et al. 2004; Oster et al. 2005). Disturbingly, despite evidence
that antiviral therapy may effectively reduce the severity and
duration of HZ if given within 72 h of rash onset (Dworkin
2006), of the 89% of respondents who received medication in
the current survey, 37% did not receive it within this
72-h window. Furthermore, despite various treatments, pain
relief was not satisfactory; mean pain relief was only 64%, with
mean pain relief of only 50% in those with PHN. One in four
respondents who received medication reported side effects.
There are several potential limitations associated with the
present study. Firstly, the survey was retrospective. Howev-
er, the design allowed the collection of data once the com-
plete HZ/PHN episode had finished. This provided a broad
picture of the patient-reported impact of HZ/PHN on QoL.
Furthermore, the retrospective nature of the study had the
benefit of a large sample size and provided data more
rapidly than prospective studies. Secondly, validated ques-
tionnaires could not be used because they prospectively
measure the impact of current HZ/PHN on QoL at specific
time points. Bespoke questions were prepared, some of
which were informed from standard QoL questionnaires
and further developed to enable evaluation of the complete
previous HZ/PHN episode. In the future, the results of the
present study could potentially inform the design of pro-
spective studies to evaluate the impact of HZ and PHN on
patients’ QoL, and questionnaires that can be used to assess
the entire episode of HZ/PHN could be validated. A third
potential limitation of this study is that the method used in
The Netherlands (online, computer-assisted self-interviews)
was different to that used in other countries (computer-
assisted telephone interviews). This might have contributed
to differences in outcomes between Dutch participants ver-
sus all respondents. Fourthly, the survey asked subjects to
recall events that occurred up to 5 years previously. How-
ever, the pain and QoL results were not affected by age or
time since diagnosis, demonstrating that HZ/PHN is a life
event that is not readily forgotten.
Until now, HZ and PHN could not be prevented. Further-
more, management modalities for acute HZ pain and PHN
remain inadequate. Vaccination is a new option to reduce
the burden of HZ/PHN. A live attenuated VZV vaccine
(ZOSTAVAX®) is indicated for the prevention of HZ and
PHN (ZOSTAVAX® 2006). By boosting VZV-specific cell-
mediated immunity (Levin et al. 1998, 1992, 2003; Oxman
1995; Trannoy et al. 2000), which naturally declines with
age (Arvin 2005; Levin et al. 2008), the vaccine acts as a
‘latent virus blocker’ controlling the reactivation and/or subse-
quent replication of latent VZV and thereby preventing HZ or
attenuating its severity (Levin et al. 2008). In the Shingles
Prevention Study, a pivotal study involving 38,546 subjects
aged ≥60 years old, vaccine efficacy was demonstrated by a
reduction of 51.3% in the prevalence of HZ (p<0.001 versus
unvaccinated individuals) and a 66.5% reduction in the preva-
lence of PHN (p<0.001 versus unvaccinated individuals;
Oxman et al. 2005, 2008). In addition to reducing the HZ/
PHN prevalence, the vaccine also reduced the burden of illness
due to HZ by 61.1% (p<0.001 versus unvaccinated individu-
als) – this measure is affected by the incidence, severity and
duration of HZ-related pain and discomfort. Importantly, these
reductions in HZ/PHN prevalence and burden of illness in
vaccinees were associated with improvements in QoL. Inter-
ference of HZ on activities of daily living was significantly
reduced by 66%, and SF-12 Mental and Physical Component
Scores (measures of health-related QoL) were both reduced by
55% (Schmader et al. 2010).
Conclusions
The results of this European survey clearly demonstrate that
HZ, and particularly PHN, are associated with considerable
levels of pain that have a significant impact on QoL. Indeed,
HZ pain/PHN not only has a direct impact on individuals, it
also affects their social life, with consequences for family
and friends, and it impacts society, in terms of loss of
productivity and associated cost implications.
Similar results in terms of pain and QoL outcomes were
achieved across seven European countries, including the
initial study in Germany (Weinke et al. 2010). Participants
across seven0 European countries were required to recall
episodes of HZ/PHN that occurred up to 5 years earlier.
Hence, these results, along with those in the initial study
(Weinke et al. 2010), indicate that HZ/PHN is a life event
that is not readily forgotten.
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